Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors-Reference-Cited by-同舟云学术

Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors

Published:2024 Issue:1 Volume:25 Page:
ISSN:1229-845X
Container-title:Journal of Veterinary Science
language:en
Short-container-title:J Vet Sci

Author:

Igase Masaya¹^ORCID,Inanaga Sakuya¹^ORCID,Nishibori Shoma¹^ORCID,Itamoto Kazuhito²^ORCID,Sunahara Hiroshi³^ORCID,Nemoto Yuki³^ORCID,Tani Kenji³^ORCID,Horikirizono Hiro⁴^ORCID,Nakaichi Munekazu⁴^ORCID,Baba Kenji⁵^ORCID,Kambayashi Satoshi⁵^ORCID,Okuda Masaru⁵^ORCID,Sakai Yusuke⁶^ORCID,Sakurai Masashi⁶^ORCID,Kato Masahiro⁷^ORCID,Tsukui Toshihiro⁷^ORCID,Mizuno Takuya¹^ORCID

Affiliation:

1. Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

2. Laboratory of Veterinary Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

3. Laboratory of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

4. Laboratory of Veterinary Radiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

5. Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

6. Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.

7. Nippon Zenyaku Kogyo Co., Ltd., Koriyama, Fukushima 963-0196, Japan.

Funder

JSPS KAKENHI

Publisher

XMLink

Subject

General Veterinary

Link

https://vetsci.org/pdf/10.4142/jvs.23144

Reference26 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

3. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

4. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

5. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma